BACKGROUND: Fc gamma receptor polymorphisms were linked to outcome in follicular lymphoma patients treated with single-agent rituximab, an anti-CD20 monoclonal antibody. In particular, 158F/F genotype of Fc gamma receptor 3A and 131R/R genotype of Fc gamma receptor 2A correlated with worse outcome compared to high-affinity 158V/V and 131H/H, respectively. We examined this association in the context of anti-CD20 monoclonal antibody combined with chemotherapy, as compared to chemotherapy alone, in follicular lymphoma patients treated on SWOG clinical trials. DESIGN AND METHODS: Tissue from 142 SWOG patients treated with chemotherapy alone (protocol S8809, n = 70) or combined chemotherapy and anti-CD20 monoclonal antibody (rituximab and Iodine I-131 tositumomab on protocols S9800 and S9911, n = 30 and 42, respectively) was analyzed. DNA was extracted and assayed for Fc gamma receptor 3A V158F and 2A R131H polymorphisms using a TaqMan SNP assay. Stratified Cox's regression was used to assess association with overall survival. RESULTS: For Fc gamma receptor 3A, there was an association with overall survival in the combination therapy trials but not in the chemotherapy-only trial. Having at least one Fc gamma receptor 3A V allele was associated with improved overall survival versus F/F (HR = 0.33, 95% CI, 0.11, 0.96, P = 0.042). For overall survival, there was evidence of a statistical interaction between the use of mAb and the number of V alleles (0, 1, or 2) (P = 0.006). There was no such association for Fc gamma receptor 2A. CONCLUSIONS: Fc gamma receptor 3A polymorphism status may be predictive of survival in follicular lymphoma patients receiving treatments containing an anti-CD20 antibody but not treatment with chemotherapy alone. Thus, Fc gamma receptor 3A polymorphisms may be important to consider in designing new follicular lymphoma trials and new anti-CD20 monoclonal antibodies. (Clinicaltrials.gov identifier: NCT00933127).
BACKGROUND:Fc gamma receptor polymorphisms were linked to outcome in follicular lymphomapatients treated with single-agent rituximab, an anti-CD20 monoclonal antibody. In particular, 158F/F genotype of Fc gamma receptor 3A and 131R/R genotype of Fc gamma receptor 2A correlated with worse outcome compared to high-affinity 158V/V and 131H/H, respectively. We examined this association in the context of anti-CD20 monoclonal antibody combined with chemotherapy, as compared to chemotherapy alone, in follicular lymphomapatients treated on SWOG clinical trials. DESIGN AND METHODS: Tissue from 142 SWOG patients treated with chemotherapy alone (protocol S8809, n = 70) or combined chemotherapy and anti-CD20 monoclonal antibody (rituximab and Iodine I-131 tositumomab on protocols S9800 and S9911, n = 30 and 42, respectively) was analyzed. DNA was extracted and assayed for Fc gamma receptor 3A V158F and 2A R131H polymorphisms using a TaqMan SNP assay. Stratified Cox's regression was used to assess association with overall survival. RESULTS: For Fc gamma receptor 3A, there was an association with overall survival in the combination therapy trials but not in the chemotherapy-only trial. Having at least one Fc gamma receptor 3A V allele was associated with improved overall survival versus F/F (HR = 0.33, 95% CI, 0.11, 0.96, P = 0.042). For overall survival, there was evidence of a statistical interaction between the use of mAb and the number of V alleles (0, 1, or 2) (P = 0.006). There was no such association for Fc gamma receptor 2A. CONCLUSIONS:Fc gamma receptor 3A polymorphism status may be predictive of survival in follicular lymphomapatients receiving treatments containing an anti-CD20 antibody but not treatment with chemotherapy alone. Thus, Fc gamma receptor 3A polymorphisms may be important to consider in designing new follicular lymphoma trials and new anti-CD20 monoclonal antibodies. (Clinicaltrials.gov identifier: NCT00933127).
Authors: Pina M Cardarelli; Maire Quinn; Dana Buckman; Yu Fang; David Colcher; David J King; Christopher Bebbington; Geoffrey Yarranton Journal: Cancer Immunol Immunother Date: 2001-12-18 Impact factor: 6.968
Authors: M Ghielmini; K Rufibach; G Salles; L Leoncini-Franscini; C Léger-Falandry; S Cogliatti; M Fey; G Martinelli; R Stahel; A Lohri; N Ketterer; M Wernli; T Cerny; S-F Hsu Schmitz Journal: Ann Oncol Date: 2005-07-19 Impact factor: 32.976
Authors: Christian Kellner; Andreas Günther; Andreas Humpe; Roland Repp; Katja Klausz; Stefanie Derer; Thomas Valerius; Matthias Ritgen; Monika Brüggemann; Jan Gj van de Winkel; Paul Whi Parren; Michael Kneba; Martin Gramatzki; Matthias Peipp Journal: Oncoimmunology Date: 2015-06-05 Impact factor: 8.110
Authors: Noa Granot; Andrew R Rezvani; Barbara S Pender; Barry E Storer; Brenda M Sandmaier; Rainer Storb; David G Maloney Journal: Biol Blood Marrow Transplant Date: 2020-07-18 Impact factor: 5.742
Authors: Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis Journal: Neurotherapeutics Date: 2020-10-14 Impact factor: 7.620
Authors: Barbara W Grant; Sin-Ho Jung; Jeffrey L Johnson; Lale Kostakoglu; Eric Hsi; John C Byrd; Jeffrey Jones; John P Leonard; S Eric Martin; Bruce D Cheson Journal: Cancer Date: 2013-08-06 Impact factor: 6.860
Authors: Tim Wirt; Sophia Rosskopf; Thies Rösner; Klara Marie Eichholz; Anne Kahrs; Sebastian Lutz; Anna Kretschmer; Thomas Valerius; Katja Klausz; Anna Otte; Martin Gramatzki; Matthias Peipp; Christian Kellner Journal: Transfus Med Hemother Date: 2017-09-11 Impact factor: 3.747